For example, a course of standard treatment (doxorubicin, cyclophosphamide, docetaxel, trastuzumab) for early-stage human epidermal growth factor receptor 2 positive (HER2+) breast cancer would cost about 10 years of average annual wages in India and South Africa (2). Here, ERBB2 is linked to breast cancer.